Logo image of 1COV.DE

COVESTRO AG (1COV.DE) Stock Fundamental Analysis

Europe - FRA:1COV - DE0006062144 - Common Stock

58.44 EUR
+0.58 (+1%)
Last: 9/26/2025, 1:39:55 PM
Fundamental Rating

2

Taking everything into account, 1COV scores 2 out of 10 in our fundamental rating. 1COV was compared to 69 industry peers in the Chemicals industry. Both the profitability and financial health of 1COV have multiple concerns. 1COV is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year 1COV has reported negative net income.
In the past year 1COV had a positive cash flow from operations.
The reported net income has been mixed in the past 5 years: 1COV reported negative net income in multiple years.
Each year in the past 5 years 1COV had a positive operating cash flow.
1COV.DE Yearly Net Income VS EBIT VS OCF VS FCF1COV.DE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 1B 2B

1.2 Ratios

Looking at the Return On Assets, with a value of -2.86%, 1COV is doing worse than 69.57% of the companies in the same industry.
The Return On Equity of 1COV (-6.14%) is worse than 69.57% of its industry peers.
Industry RankSector Rank
ROA -2.86%
ROE -6.14%
ROIC N/A
ROA(3y)-1.76%
ROA(5y)1.73%
ROE(3y)-3.61%
ROE(5y)3.67%
ROIC(3y)N/A
ROIC(5y)N/A
1COV.DE Yearly ROA, ROE, ROIC1COV.DE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10 20 30

1.3 Margins

In the last couple of years the Operating Margin of 1COV has declined.
1COV has a Gross Margin of 14.09%. This is in the lower half of the industry: 1COV underperforms 78.26% of its industry peers.
1COV's Gross Margin has declined in the last couple of years.
1COV does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 14.09%
OM growth 3Y-78.51%
OM growth 5Y-54.06%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-18%
GM growth 5Y-7.1%
1COV.DE Yearly Profit, Operating, Gross Margins1COV.DE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10 20 30

More info and screens

3

2. Health

2.1 Basic Checks

1COV does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for 1COV remains at a similar level compared to 1 year ago.
Compared to 5 years ago, 1COV has more shares outstanding
Compared to 1 year ago, 1COV has an improved debt to assets ratio.
1COV.DE Yearly Shares Outstanding1COV.DE Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M
1COV.DE Yearly Total Debt VS Total Assets1COV.DE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5B 10B 15B

2.2 Solvency

1COV has an Altman-Z score of 2.31. This is not the best score and indicates that 1COV is in the grey zone with still only limited risk for bankruptcy at the moment.
With a Altman-Z score value of 2.31, 1COV perfoms like the industry average, outperforming 53.62% of the companies in the same industry.
1COV has a Debt/Equity ratio of 0.34. This is a healthy value indicating a solid balance between debt and equity.
Looking at the Debt to Equity ratio, with a value of 0.34, 1COV is in the better half of the industry, outperforming 63.77% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.34
Debt/FCF N/A
Altman-Z 2.31
ROIC/WACCN/A
WACC6.39%
1COV.DE Yearly LT Debt VS Equity VS FCF1COV.DE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2B 4B 6B

2.3 Liquidity

A Current Ratio of 1.39 indicates that 1COV should not have too much problems paying its short term obligations.
1COV has a worse Current ratio (1.39) than 66.67% of its industry peers.
A Quick Ratio of 0.74 indicates that 1COV may have some problems paying its short term obligations.
With a Quick ratio value of 0.74, 1COV is not doing good in the industry: 79.71% of the companies in the same industry are doing better.
Industry RankSector Rank
Current Ratio 1.39
Quick Ratio 0.74
1COV.DE Yearly Current Assets VS Current Liabilites1COV.DE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2B 4B 6B

More info and screens

3

3. Growth

3.1 Past

The earnings per share for 1COV have decreased strongly by -17.54% in the last year.
The Revenue has decreased by -1.98% in the past year.
Measured over the past years, 1COV shows a small growth in Revenue. The Revenue has been growing by 2.70% on average per year.
EPS 1Y (TTM)-17.54%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%18.42%
Revenue 1Y (TTM)-1.98%
Revenue growth 3Y-3.75%
Revenue growth 5Y2.7%
Sales Q2Q%-8.43%

3.2 Future

1COV is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 25.97% yearly.
Based on estimates for the next years, 1COV will show a small growth in Revenue. The Revenue will grow by 0.77% on average per year.
EPS Next Y18.76%
EPS Next 2Y66.71%
EPS Next 3Y51.85%
EPS Next 5Y25.97%
Revenue Next Year-4.3%
Revenue Next 2Y-0.18%
Revenue Next 3Y1.27%
Revenue Next 5Y0.77%

3.3 Evolution

The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
1COV.DE Yearly Revenue VS Estimates1COV.DE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 5B 10B 15B
1COV.DE Yearly EPS VS Estimates1COV.DE Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 2 4 6 8

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

1COV reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
With a Price/Forward Earnings ratio of 52.82, 1COV can be considered very expensive at the moment.
1COV's Price/Forward Earnings ratio is a bit more expensive when compared to the industry. 1COV is more expensive than 69.57% of the companies in the same industry.
1COV is valuated expensively when we compare the Price/Forward Earnings ratio to 22.64, which is the current average of the S&P500 Index.
Industry RankSector Rank
PE N/A
Fwd PE 52.82
1COV.DE Price Earnings VS Forward Price Earnings1COV.DE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20 40

4.2 Price Multiples

1COV's Enterprise Value to EBITDA ratio is a bit more expensive when compared to the industry. 1COV is more expensive than 66.67% of the companies in the same industry.
Industry RankSector Rank
P/FCF N/A
EV/EBITDA 15.76
1COV.DE Per share data1COV.DE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 20 40 60

4.3 Compensation for Growth

The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates 1COV does not grow enough to justify the current Price/Earnings ratio.
1COV's earnings are expected to grow with 51.85% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y66.71%
EPS Next 3Y51.85%

More info and screens

0

5. Dividend

5.1 Amount

1COV does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

COVESTRO AG

FRA:1COV (9/26/2025, 1:39:55 PM)

58.44

+0.58 (+1%)

Chartmill FA Rating
GICS SectorMaterials
GICS IndustryGroupMaterials
GICS IndustryChemicals
Earnings (Last)07-31 2025-07-31/bmo
Earnings (Next)10-30 2025-10-30
Inst Owners41.76%
Inst Owner ChangeN/A
Ins Owners0.03%
Ins Owner ChangeN/A
Market Cap11.05B
Analysts49.47
Price Target62.08 (6.23%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly Dividend0.01
Dividend Growth(5Y)-70.61%
DP-0.26%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-681.03%
Min EPS beat(2)-1222.75%
Max EPS beat(2)-139.31%
EPS beat(4)1
Avg EPS beat(4)-330.2%
Min EPS beat(4)-1222.75%
Max EPS beat(4)201.01%
EPS beat(8)1
Avg EPS beat(8)-4314.94%
EPS beat(12)2
Avg EPS beat(12)-2882.46%
EPS beat(16)4
Avg EPS beat(16)-2161.83%
Revenue beat(2)0
Avg Revenue beat(2)-5.71%
Min Revenue beat(2)-6.91%
Max Revenue beat(2)-4.5%
Revenue beat(4)0
Avg Revenue beat(4)-5.8%
Min Revenue beat(4)-6.91%
Max Revenue beat(4)-4.5%
Revenue beat(8)0
Avg Revenue beat(8)-4.99%
Revenue beat(12)1
Avg Revenue beat(12)-3.71%
Revenue beat(16)4
Avg Revenue beat(16)-2.08%
PT rev (1m)-1.69%
PT rev (3m)-1.38%
EPS NQ rev (1m)-3%
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)-462.35%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)-1.99%
Revenue NY rev (3m)-6.29%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 52.82
P/S 0.8
P/FCF N/A
P/OCF 14.57
P/B 1.8
P/tB 2.2
EV/EBITDA 15.76
EPS(TTM)-2.01
EYN/A
EPS(NY)1.11
Fwd EY1.89%
FCF(TTM)-0.61
FCFYN/A
OCF(TTM)4.01
OCFY6.86%
SpS73.2
BVpS32.56
TBVpS26.55
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -2.86%
ROE -6.14%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 14.09%
FCFM N/A
ROA(3y)-1.76%
ROA(5y)1.73%
ROE(3y)-3.61%
ROE(5y)3.67%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)1.42%
ROCE(5y)6.03%
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3Y-78.51%
OM growth 5Y-54.06%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-18%
GM growth 5Y-7.1%
F-Score4
Asset Turnover1.05
Health
Industry RankSector Rank
Debt/Equity 0.34
Debt/FCF N/A
Debt/EBITDA 2.39
Cap/Depr 88.46%
Cap/Sales 6.32%
Interest Coverage N/A
Cash Conversion 85.65%
Profit Quality N/A
Current Ratio 1.39
Quick Ratio 0.74
Altman-Z 2.31
F-Score4
WACC6.39%
ROIC/WACCN/A
Cap/Depr(3y)75.52%
Cap/Depr(5y)82.02%
Cap/Sales(3y)5.15%
Cap/Sales(5y)5.37%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-17.54%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%18.42%
EPS Next Y18.76%
EPS Next 2Y66.71%
EPS Next 3Y51.85%
EPS Next 5Y25.97%
Revenue 1Y (TTM)-1.98%
Revenue growth 3Y-3.75%
Revenue growth 5Y2.7%
Sales Q2Q%-8.43%
Revenue Next Year-4.3%
Revenue Next 2Y-0.18%
Revenue Next 3Y1.27%
Revenue Next 5Y0.77%
EBIT growth 1Y-183.74%
EBIT growth 3Y-79.32%
EBIT growth 5Y-52.83%
EBIT Next Year364.32%
EBIT Next 3Y92.23%
EBIT Next 5Y45.82%
FCF growth 1Y-126.73%
FCF growth 3Y-60.36%
FCF growth 5Y-28.37%
OCF growth 1Y-37.61%
OCF growth 3Y-26.52%
OCF growth 5Y-8.84%